A Spanish-based KOL provides insight into the treatment pathway of triple-negative breast cancer with a focus on the beneficial impacts of Keytruda for early-stage patients. The KOL also highlights the promise of personalized vaccines and bispecific antibodies, as well as key data from late-phase clinical trials. 

This interview was conducted on Aug. 22, 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.